
-
'Makes no sense': Hollywood shocked by Trump's film tariffs announcement
-
First day of jury selection wraps in Sean Combs sex crimes trial
-
Dominican Republic reports sharp rise in Haitian migrant deportations
-
Mennonite communities raise hackles in Peruvian Amazon
-
Dominican Republican reports sharp rise in Haitian migrant deportations
-
Stars shine at Met Gala, showcasing Black dandyism
-
Ireland captain Doris doubtful for Lions tour due to shoulder injury
-
Pentagon chief orders 20% cut in number of top officers
-
'New superstar' Zhao's world title heralds Chinese snooker revolution
-
OpenAI abandons plan to become for-profit company
-
Ford sees $1.5 bn tariff hit this year, suspends 2025 forecast
-
Snooker star Zhao: from ban to Chinese sporting history
-
Zhao makes history as China's first World Snooker champion
-
Brazilian ritual root gets second life as potential anti-depressant
-
Israel says 'most' Gazans to be displaced in expanded operation
-
Israel strikes Yemen after Huthi attack on Ben Gurion airport
-
'It's time': Popovich passes Spurs torch to Johnson
-
Cummins heroics in vain as rain forces Hyderabad out of IPL playoff race
-
Huthis say US, Israel bomb Yemen after strike on Israeli airport
-
Lewandowski on bench for Barca's showdown with Inter, says coach Flick
-
Pricing birdsong: EU mulls nature credits to help biodiversity
-
Scholz vows continued German support in last call with Zelensky
-
UK kicks off party to mark 80 years since end of WWII
-
Global film industry reels from Trump tariff announcement
-
Cardinals assemble to elect pope and set course for church
-
Meta content moderator cuts over 2,000 jobs in Spain: union
-
Pakistan conducts second missile test, India readies civil defence drills
-
Pro-EU or pro-Trump? Romania faces decisive choice in vote
-
Nazi surrender site sets the scene for Wim Wenders short film
-
French court backs Olympics choreographer in cyberbullying case
-
Romania run-off pits pro-Trump nationalist against centrist mayor
-
South Africa's Rabada back in IPL after serving drug ban
-
Pride and excitement as UK crowds celebrate 80 years since WWII's end
-
Ex-French interior minister Darmanin apologises for 2022 Champions League fiasco
-
Zhao on brink of becoming China's first World Snooker champion
-
Stars come out for Met Gala, showcasing Black dandyism
-
Jury selection begins in Sean 'Diddy' Combs sex crimes trial
-
Martinez rushing to be ready for Barca showdown, says Inter's Inzaghi
-
Warren Buffett to remain as Berkshire Hathaway board chair
-
UK royals lead celebrations to mark 80 years since WWII end
-
Top Spanish court drops tax complaint against ex-king Juan Carlos
-
Who are the Middle East's Druze religious community?
-
Russian reporter critical of Ukraine war escapes to France
-
France names first Concorde jet a historical monument
-
France, EU take aim at Trump's assault on science, seek to lure US researchers
-
Catholic Church's direction in the balance as vote conclave looms
-
German coalition deal signed on eve of Merz govt launch
-
UK begins four days of events to honour last WWII veterans
-
Cassocks competition: whose outfit will new pope wear?
-
Traditional culture, fancy dress meet at Hong Kong's raucous bun festival

Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
A.Malone--AMWN